Serum Levels of TNFAIP3 and NLRP3 as Novel Biomarkers for Major Adverse Cardiovascular Events in Patients with Chronic Heart Failure: A Cohort Study
Degang Mo, Lijia Yang, Peng Zhang, Miao Zhang, Jun Guan, Guoan Wang, Hongyan Dai · 2025
Read Serum Levels of TNFAIP3 and NLRP3 as Novel Biomarkers for Major Adverse Cardiovascular Events in Patients with Chronic Heart Failure: A Cohort Study by Degang Mo, Lijia Yang, Peng Zhang, Miao Zhang, Jun Guan, Guoan Wang, Hongyan Dai (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12719054.txt.
Description
Degang Mo and six co-authors published a 2025 cohort study of two blood markers in chronic heart failure. Inflammation drives much of the damage in heart failure. The team measured TNFAIP3, a protein that restrains inflammation, and NLRP3, a protein that promotes it, in 318 patients and 122 healthy controls.
Patients had higher levels of both markers than controls. Over six months, patients who suffered major heart events had lower TNFAIP3 and higher NLRP3 than those who stayed event-free. Statistical tests confirmed each marker predicted events on its own. NLRP3 was the stronger predictor of the two. The authors suggest blood tests for these proteins could help flag high-risk patients early.
Catalog record
| CREATOR | Degang Mo, Lijia Yang, Peng Zhang, Miao Zhang, Jun Guan, Guoan Wang, Hongyan Dai |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |